GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » Abrdn Equity Income Trust PLC (CHIX:AEIl) » Definitions » Research & Development

Abrdn Equityome Trust (CHIX:AEIL) Research & Development : £0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Abrdn Equityome Trust Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Abrdn Equityome Trust's Research & Development for the six months ended in Sep. 2024 was £0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was £0.00 Mil.

Abrdn Equityome Trust Research & Development Historical Data

The historical data trend for Abrdn Equityome Trust's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abrdn Equityome Trust Research & Development Chart

Abrdn Equityome Trust Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Abrdn Equityome Trust Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Abrdn Equityome Trust Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abrdn Equityome Trust  (CHIX:AEIl) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Abrdn Equityome Trust Research & Development Related Terms

Thank you for viewing the detailed overview of Abrdn Equityome Trust's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Abrdn Equityome Trust Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » Abrdn Equity Income Trust PLC (CHIX:AEIl) » Definitions » Research & Development
Comparable Companies
LSE:BGCG LSE:FTF LSE:TORO LSE:OIG LSE:MGCI LSE:BSC LSE:PGOO LSE:LTI LSE:PVN LSE:MMIT BLK BX KKR OSTO:INVE A TSX:BAM APO TSX:BN LSE:III AMP XSWX:PGHN
Traded in Other Exchanges
AEI:UK
Address
280 Bishopsgate, London, GBR, EC2M 4AG
Website
https://www.abrdn.com
Abrdn Equity Income Trust PLC is an investment trust company. Its investment objective is to provide shareholders with an above average income from their equity investment and provide real growth in capital and income. Its investment portfolio comprises convertible preference shares, convertible loan stocks, gilts, and corporate bonds. The company's portfolio is diversified across various sectors such as Oil and Gas, Basic Materials, Industrials, Consumer Goods, Healthcare, Consumer Services, Telecommunications, Utilities, Financials, and technology.

Abrdn Equityome Trust Headlines

No Headlines